http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022112270-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_70e16ee5cc9d1385aa4be6cd263f63a3 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-8125 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-81 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 |
| filingDate | 2021-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e303722dab26cb5f96bb4a04c26ca23 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c4ee11d110a678869228e813a83397e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9960b33706c195cd8ac9811ea58fb945 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a25e7a09ede2873a389089f9c042cdd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fcffc1b049d60159ef89c98e1e7b5347 |
| publicationDate | 2022-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2022112270-A1 |
| titleOfInvention | Methods of producing and using recombinant alpha 1-antitrypsin (aat) and compositions thereof |
| abstract | Embodiments of the present invention generally relate to recombinant alpha 1-antitrypsin (AAT) proteins, including variants of human AAT with individually introduced mutations, compositions containing such recombinant AAT proteins and carriers, expression plasmids or vectors and host cells that express such recombinant AAT proteins, methods of producing such recombinant AAT proteins, and methods of treating AAT deficiency-related diseases, disorders, and conditions or diseases, disorders, and conditions resulting in protease-induced tissue damage in a subject in need thereof with the recombinant AAT proteins and/or recombinant AAT protein compositions described here. The recombinant AAT proteins derived from mammalian host cells as produced by the methods described here may be produced in large quantities, without any animal components, i.e., highly pure, highly glycosylated, and may be advantageously used over plasma-derived AAT. |
| priorityDate | 2019-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 764.